News

Medscape36m
FDA Approves Penpulimab for Nasopharyngeal Cancer
Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...
Fierce Pharma1h
Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype
Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...
Contract Pharma2h
FDA Approves Akeso’s Penpulimab for Nasopharyngeal Carcinoma
The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.
RFK Jr. recounts heroin addiction and spiritual awakening, urges focus on prevention and community
Health and Human Services Secretary Robert F. Kennedy Jr. told a personal story of his own heroin addiction and recovery at a ...
Boing Boing on MSN4h
After delays, Novavax Covid vaccine is on track for full FDA approval
Rejoice, fellow vaccine enthusiasts-it looks like there's good news on the horizon for Novavax, everyone's favorite scrappy, ...
Vietnam Investment Review on MSN11h
FDA Approves Akeso s Penpulimab for Dual Use in Nasopharyngeal Cancer Treatment
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in ...